ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2020
Circulating Irisin Levels as a Marker of Osteosarcopenic-Obesity in Cushing's Disease.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Targeting the PINK1/Parkin-FNDC5 pathway: a novel mechanism of icariin in regulating muscle-bone metabolic coupling in osteosarcopenia.Journal of translational medicine · 2026Article
- Irisin: A Multifaceted Hormone Bridging Exercise and Disease Pathophysiology.International journal of molecular sciences · 2024Review
- New insights into the vitamin D/PTH axis in endocrine-driven metabolic bone diseases.Endocrine · 2024Review
- Prevalence of Osteosarcopenic Adiposity in Apparently Healthy Adults and Appraisal of Age, Sex, and Ethnic Differences.Journal of personalized medicine · 2024Article
- Nutritional Intervention in Cushing's Disease: The Ketogenic Diet's Effects on Metabolic Comorbidities and Adrenal Steroids.Nutrients · 2023Article
- Muscle-bone crosstalk via endocrine signals and potential targets for osteosarcopenia-related fracture.Journal of orthopaedic translation · 2023Review
- Understanding the Consequences of Fatty Bone and Fatty Muscle: How the Osteosarcopenic Adiposity Phenotype Uncovers the Deterioration of Body Composition.Metabolites · 2023Review
- Irisin: A Possible Marker of Adipose Tissue Dysfunction in Obesity.International journal of molecular sciences · 2023Article
- Irisin and Bone in Sickness and in Health: A Narrative Review of the Literature.Journal of clinical medicine · 2022Review
- Very Low-Calorie Ketogenic Diet: A Potential Application in the Treatment of Hypercortisolism Comorbidities.Nutrients · 2022Review
- A Bibliometric Analysis of the Literature on Irisin from 2012-2021.International journal of environmental research and public health · 2022Review
- Vitamin D in Osteosarcopenic Obesity.Nutrients · 2022Review
- Article
- Irisin and Secondary Osteoporosis in Humans.International journal of molecular sciences · 2022Review
- Myokines in Acromegaly: An Altered Irisin Profile.Frontiers in endocrinology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate circulating irisin levels in patients with active and controlled Cushing's disease (CD).
designForty-four patients with CD evaluated during the active phase and after 12 months of biochemical remission and 40 controls were recruited.
methodsPhenotypic, anthropometric, hormonal and metabolic parameters, including insulin sensitivity estimation by homeostatic model of insulin resistance, Matsuda index and oral disposition index and circulating irisin levels were evaluated.
resultsPatients with active CD showed lower irisin levels compared to controls (p<0.001) and controlled CD (p<0.001). The independent variables significantly associated with irisin were waist circumference (WC) (p=0.025), body fat percentage (BF%) (p=0.009), PTH (p=0.007) and chair rising test (CRT) (p<0.001) in active CD and WC (p=0.013), BF% (p=0.014), PTH (p=0.038), CRT (p=0.029) and urinary-free cortisol (p<0.001) in controlled CD.
conclusionCirculating irisin levels tend to be lower in patients with active CD compared to those with controlled CD and controls. They are strongly associated with osteosarcopenia and central obesity in CD and therefore may be a possible marker of diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.